Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04675645 · ClinicalTrials.gov registry record · NA

Adherence to HU and HRQOL in Patients With Sickle Cell Disease: An Intervention Study Using HU-Go App

A NA study, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

Completed
Registry status
NA
Development phase
33
Enrollment target

NCT04675645 is a NA study that has completed, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 33 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04675645, a NA study, has completed, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

COMPLETED
Registry status
NA
Development phase
33 participants
Enrollment target

Study Summary

This project addresses three important research questions. First, adolescents and young adults (AYA) with sickle cell disease (SCD) and their parents/caregivers will be engaged to inform the (1) domains of health-related quality of life (HRQOL) most important to them, (2) frequency at which they are willing to complete them, and (3) other procedures related to the use, uptake and effect of the HU-Go app as a tool to improve hydroxyurea (HU) adherence. Second, this study seeks to utilize novel modern mobile technology using a multi-functional personalized platform to improve adherence to HU and measure HRQOL in youth with SCD, using NIH-endorsed PROMIS® measures, based on a conceptual model with predefined behavioral targets and mediators. Third, we plan to assess HRQOL changes and identify modifiable behavioral strategies that could serve as surrogates or predictors for HU adherence. This real-time feedback might empower self-directed changes in behavior that could improve adherence to HU.

Interventions

  • OTHER HU-Go app

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2018-05-15
Est. Completion 2020-07-11
Phase NA

What the Registry Record Tells You About NCT04675645

The ClinicalTrials.gov registry entry for NCT04675645 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which HU-Go app is the first listed.

NCT04675645 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04675645 about?

NCT04675645 is a clinical study titled "Adherence to HU and HRQOL in Patients With Sickle Cell Disease: An Intervention Study Using HU-Go App". This project addresses three important research questions. First, adolescents and young adults (AYA) with sickle cell disease (SCD) and their parents/caregivers will be engaged to inform the (1) domains of health-related quality of life (HRQOL) most important to them, (2) frequency at which they are...

What is the current status of trial NCT04675645?

This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2018-05-15. Estimated completion is 2020-07-11.

What interventions are being tested in trial NCT04675645?

The interventions under investigation include: HU-Go app (OTHER).

Who is sponsoring clinical trial NCT04675645?

This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.